New data showed that rinatabart sesutecan (Rina-S®) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 months Continued evaluation of single-agent Rina-S 100 mg/m2 in patients with advanced...
Latest News
COPENHAGEN, Denmark – Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a monotherapy and in combination with other standard of care treatments in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Results from two arms of the EPCORE® NHL-2 trial, evaluating first-line,...
COPENHAGEN, Denmark – Genmab A/S (Nasdaq: GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the safety and efficacy of investigational epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy administered in the outpatient setting in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one...
COPENHAGEN, Denmark – Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment...
Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability. Results are attained without requiring lymphodepletion. SHENZHEN, China — Genocury Biotech today revealed groundbreaking clinical data from its noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL),...
Genomenon, Inc.®, an AI-driven genomics company, today announced a collaboration with Alexion, AstraZeneca Rare Disease that will make critical information needed for the diagnosis and treatment for a set of rare diseases more readily accessible. The goal of this collaboration is to empower genetic testing labs with the data they need to...
Tokyo, Japan – Researchers in the RIKEN Center for Brain Science (CBS) examined the genetics of autism spectrum disorder (ASD) by analyzing mutations in the genomes of individuals and their families. They discovered that a special kind of genetic mutation works differently from typical mutations in how it contributes to...
DANVILLE, Pa. – Genomic screening to identify hemochromatosis—a disorder that causes iron levels in the body to rise to dangerous levels—encourages people with the condition to seek treatment and ongoing management, a Geisinger study found. Hereditary hemochromatosis type 1 (HH1), caused by a change in the HFE gene, is underdiagnosed, often...
Exclusive rights for novel early-stage asset in cholangiocarcinoma have been acquired by GENFIT in these territories Phase 2 clinical program in cholangiocarcinoma expected to start the first half of 2022 Genoscience Pharma pursues the development with GNS561 in other oncology indications; will start phase 2 in hepatocarcinoma in 2022 Marseille,...
AUSTIN, Texas — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that in January 2024, the first patient was enrolled and dosed in the Phase 2a expansion portion of the Company’s Acclaim-1 clinical study of Reqorsa® Therapy...